News Medical on MSN1d
Daily drug can mimic health benefits of high-altitude, low-oxygen living for mitochondrial diseaseFor the average person, living at high altitude—where oxygen is sparser than at sea level—can have health benefits ranging ...
Q4 2024 Earnings Call Transcript February 13, 2025 Operator: Good morning, and welcome to Agios’ Fourth Quarter 2024 ...
Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.
Scientists at Gladstone Institutes have developed a drug that mimics the effects of breathing low oxygen. In mice with Leigh ...
USA-based Agios Pharmaceuticals has announced that the ACTIVATE-Kids Phase III study of mitapivat in children aged 1 to <18 ...
The Urban League of Greater Madison and The American Red Cross will host a Sickle Cell Awareness Blood Drive on Saturday, Feb ...
An SCD patient in Bahrain received the gene-editing therapy Casgevy, marking the first time the treatment has been given outside the U.S.
In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...
Hosted on MSN1h
CHOP doctors named 'Disruptors of the Year' for groundbreaking sickle cell gene therapyThe Philadelphia Citizen is recognizing CHOP doctors Alexis Thompson and Dr. Stephan Grupp with the 'Disruptors of the Year' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback